Regeneron Pharmaceuticals' Enterprise Value rose 451.93% to -$8.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.6 billion, marking a year-over-year increase of 451.93%. This contributed to the annual value of -$8.6 billion for FY2025, which is 451.93% up from last year.
As of Q4 2025, Regeneron Pharmaceuticals' Enterprise Value stood at -$8.6 billion, which was up 451.93% from -$8.4 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Enterprise Value registered a high of -$3.5 billion during Q1 2021, and its lowest value of -$10.8 billion during Q4 2023.
Over the past 5 years, Regeneron Pharmaceuticals' median Enterprise Value value was -$8.4 billion (recorded in 2025), while the average stood at -$7.9 billion.
Per our database at Business Quant, Regeneron Pharmaceuticals' Enterprise Value plummeted by 10122.72% in 2022 and then surged by 2384.95% in 2025.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Enterprise Value stood at -$5.7 billion in 2021, then plummeted by 35.96% to -$7.7 billion in 2022, then tumbled by 40.07% to -$10.8 billion in 2023, then increased by 16.9% to -$9.0 billion in 2024, then grew by 4.52% to -$8.6 billion in 2025.
Its Enterprise Value was -$8.6 billion in Q4 2025, compared to -$8.4 billion in Q3 2025 and -$7.5 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value